Study of Blood Redox Status and Disease Progression in Adults with Autoimmune Rheumatic Diseases

What this Trial Is About

Autoimmune rheumatic diseases ARDs are chronic inflammatory conditions that include rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, myositis, Sjogrens syndrome, and systemic scleroderma. These diseases cause joint damage and affect the body systemically, often alongside other health issues like cardiovascular disease and obesity. Researchers are studying the role of oxidative stress, a condition caused by an imbalance of free radicals and antioxidants in the blood, to better understand disease progression and improve monitoring methods for ARDs. This observational study will assess specific redox biomarkers in the blood of patients with ARDs at three time points Day 1, Day 180, and Day 360. These biomarkers include reduced glutathione, catalase enzyme activity, total antioxidant capacity, and protein carbonyl concentration. In addition, inflammation markers like C-reactive protein and erythrocyte sedimentation rate will be measured. The study also collects data on physical activity, health status, quality of life, fatigue, sleep quality, nutritional habits, and medication history to explore their relationship with disease progression. Participants will provide blood samples and complete questionnaires at the three scheduled visits over one year. The study will evaluate changes in biomarker levels and clinical measures of disease severity, such as DAS28, PASI, and SLEDAI scores. This comprehensive assessment aims to determine whether redox biomarkers can serve as useful tools for tracking ARD progression. The study is sponsored by the University of Thessaly and plans to conclude by October 2026.

Oxidative Stress in Autoimmune Rheumatic Diseases